The COVID-19 pandemic presents an urgent need to investigate whether existing drugs can enhance or even worsen prognosis. Metformin, a known mammalian target of rapamycin (m-TOR) inhibitor (or in layman terms, medication to control high blood glucose levels) has been identified as a potential agent. In nursing home residents infected with SARS-CoV-2, taking metformin was associated with lower 30-day mortality relative to SARS-Co-V2 infected …